Rome

• Study of SKB264 in patients with advanced and hard-to-treat cancers who have not responded well to standard treatments. Ended
  2023-508700-38-00 4 Metastatic or locally advanced unresectable solid tumors progressing a
• Double-blind, Randomized, Placebo-controlled Study Evaluating Efficacy and Safety of IgPro20 in post-COVID-19 POTS Ended
  2023-508744-22-00 5 Post-COVID-19 Postural Orthostatic Tachycardia Syndrome
• Phase 3 Study of Tamibarotene Plus Azacitidine in Patients Selected for RARA-positive Higher-risk MDS (SELECT-MDS-1) Ended
  2023-510361-97-00 5 Newly Diagnosed RARA-positive Adult Patients with Higher-risk Myelodys
• A study to investigate the efficacy and safety of luveltamab tazevibulin versus IC chemotherapy in women with ovarian cancer (including fall … Ended
  2024-512477-27-00 4 Advanced Epithelial Ovarian Cancer (including Fallopian Tube or Primar
• PembrolizuMab beyond RECIST progression and oral metroNOmic cyclophosphamide in meTAstatic UROthelial cancer: a single-arm, monocentre, phas … Ended
  2024-514979-17-04 4 metastatic urothelial cancer
• Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men Ended
  2024-518159-52-02 10 Hypogonadotropic hypogonadism
• Electrochemotherapy as a first line treatment in recurrent squamous cell carcinoma of the oral cavity and oropharynx: a randomized controlle … Ended
  2025-520735-16-00 4 CARCINOMA OF THE ORAL CAVITY AND OROPHARYNX
• Oxytocin for drug relapse prevention Expired
  2023-504518-31-00 4 substance use disorder

Showing 2,089–2,096 of 2,096 trials